Literature DB >> 8349167

Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer.

D M Provencher1, C L Finstad, P E Saigo, S C Rubin, W J Hoskins, M G Federici, E Stockert, K O Lloyd, J L Lewis.   

Abstract

The antigenic phenotype of malignant cells from ascites of patients with epithelial ovarian cancers was examined and compared to that of their primary and metastatic sites. Cell-surface antigens on frozen sections of primary and metastatic tumors and frozen cell pellets from ascites were analyzed with a panel of murine monoclonal antibodies using the indirect immunoperoxidase method. In addition, ascites cells cultured with and without autologous cell-free ascitic fluid were evaluated by immunofluorescence. The pattern of antigen expression detected on fresh and cultured ascitic epithelial cells was shown to be identical to the expression in autologous solid tumor tissues. When placed in culture, malignant epithelial cells generally persisted for a minimum of one, but no more than five, passages. Addition of autologous ascitic fluid to cultures of ascites cells did not alter the phenotype of the epithelial tumor cell population and did not enhance the growth of these cells. From one culture of ascites cells a permanent malignant epithelial ovarian cancer cell line (designated SK-OV-8) was established. The demonstration that epithelial tumor cells found in ascites of patients with epithelial ovarian cancer have the identical antigenic phenotype as their solid tumor counterpart, at least for the panel of antigens studied, may be useful in planning imaging and therapeutic trials with monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349167     DOI: 10.1006/gyno.1993.1167

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Characterization of four novel epithelial ovarian cancer cell lines.

Authors:  D M Provencher; H Lounis; L Champoux; M Tétrault; E N Manderson; J C Wang; P Eydoux; R Savoie; P N Tonin; A M Mes-Masson
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-06       Impact factor: 2.416

2.  Establishment of a New Ovarian Cancer Cell Line CA5171.

Authors:  Ying-Cheng Chiang; Wen-Fang Cheng; Ming-Cheng Chang; Tzu-Pin Lu; Kuan-Ting Kuo; Hsiu-Ping Lin; Chang-Yao Hsieh; Chi-An Chen
Journal:  Reprod Sci       Date:  2014-11-12       Impact factor: 3.060

3.  Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.

Authors:  Martin Bezler; Jan G Hengstler; Axel Ullrich
Journal:  Mol Oncol       Date:  2012-07-20       Impact factor: 6.603

Review 4.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

Review 5.  Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin.

Authors:  Seyed Mehdi Havaei; Marc G Aucoin; Ali Jahanian-Najafabadi
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

6.  Characterization of three new serous epithelial ovarian cancer cell lines.

Authors:  Véronique Ouellet; Magdalena Zietarska; Lise Portelance; Julie Lafontaine; Jason Madore; Marie-Line Puiffe; Suzanna L Arcand; Zhen Shen; Josée Hébert; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2008-05-28       Impact factor: 4.430

7.  Effective recovery of highly purified CD326(+) tumor cells from lavage fluid of patients treated with a novel cell-free and concentrated ascites reinfusion therapy (KM-CART).

Authors:  Yukino Kimura; Yui Harada; Noriko Yasuda; Takefumi Ishidao; Seiichi Yusa; Keisuke Matsusaki; Yoshikazu Yonemitsu
Journal:  Springerplus       Date:  2015-12-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.